Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease
NC Bodick, WW Offen, AI Levey, NR Cutler… - Archives of …, 1997 - jamanetwork.com
Objective: To evaluate the therapeutic effects of selective cholinergic replacement with
xanomeline tartrate, an ml and m4 selective muscarinic receptor (mAChR) agonist in
patients with probable Alzheimer disease (AD). Design: A 6-month, randomized, double-
blind, placebocontrolled, parallel-group trial followed by a 1-month, single-blind, placebo
washout. Setting: Outpatients at 17 centers in the United States and Canada. Participants: A
total of 343 men and women at least 60 years of age with mild to moderate AD …
xanomeline tartrate, an ml and m4 selective muscarinic receptor (mAChR) agonist in
patients with probable Alzheimer disease (AD). Design: A 6-month, randomized, double-
blind, placebocontrolled, parallel-group trial followed by a 1-month, single-blind, placebo
washout. Setting: Outpatients at 17 centers in the United States and Canada. Participants: A
total of 343 men and women at least 60 years of age with mild to moderate AD …